TABLE 2.

Effect of mGluR agonists on the three components of the fEPSP

Drug Applied	Specificity	N2, Pulse 1	N2, Pulse 2	N3, Pulse 2
aCSF	None	97.5 ± 2.3	104.7 ± 4.3	95.4 ± 9.5
ACPD	Groups I, II, and III	72.9 ± 6.4*	108.9 ± 7.5	20.9 ± 12.7*
DHPG	Group I	95.8 ± 4.4	92.7 ± 1.2	83.5 ± 14.0
APDC	Group II	103.4 ± 3.6	128.4 ± 14.0	75.9 ± 18.5
l-AP4, 0.25 μM	Group III	77.1 ± 4.1*	98.0 ± 5.8	25.5 ± 31.2*
l-AP4, 2.5 μM	Group III	50.1 ± 8.8*	77.9 ± 12.5*	2.3 ± 1.6*
ACPT-III	mGluR4a	48.1 ± 3.3*	87.0 ± 5.4	11.5 ± 11.5*
Homo AMPA	mGluR6	97.9 ± 4.4	103.2 ± 5.1	93.2 ± 7.4
AMN-082	mGluR7	96.6 ± 3.8	99.8 ± 2.1	110.1 ± 13.6
PPG	mGluR8	76.4 ± 8.3	90.6 ± 5.0	16.9 ± 9.7*

Values are means±SE. Each value is the average of at least three cases. This table shows how drugs affected the amplitudes of all three potentials that were quantified. Measurements were standardized to baseline levels; 100 means no change occurred from baseline. Asterisks denote significance at P < 0.05.